Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
AssigneeChiron Corporation
InventorsChristoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
Life of this patent
Estimating the term…
Abstract
Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
Claims9
An isolated laminin5beta3 inhibitor comprising an antisense molecule, the antisense molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2 and 3.
A composition, comprising a therapeutically effective amount of a laminin5beta3 inhibitor in a pharmaceutically acceptable carrier, wherein the laminin5beta3 inhibitor is an antisense molecule and comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 2 and 3.
A method of decreasing the expression of laminin5beta3 in a mammalian cell, comprising administering to said cell an antisense molecule, wherein said antisense molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2 and 3.
A diagnostic kit for detecting the presence of a tumor cell of epithelial origin in a biological sample, said kit comprising at least one oligonucleotide selected from the group consisting of SEQ ID NOs:2 and 3, and at least one control oligonucleotide that does not hybridize with a polynucleotide of SEQ ID NO:1 under stringent conditions.
An antisense oligonucleotide that inhibits the expression of laminin5beta3 encoded by SEQ ID NO:1 wherein said antisense oligionucleotide hybridizes to said SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.